LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 52

Search options

  1. Article ; Online: Trends in Automated Peritoneal Dialysis Prescriptions in a Large Dialysis Organization in the United States.

    Giles, Harold E / Parameswaran, Vidhya / Lasky, Rachel / Ficociello, Linda H / Mullon, Claudy / Chatoth, Dinesh K / Kraus, Michael / Anger, Michael S

    Clinical journal of the American Society of Nephrology : CJASN

    2024  

    Language English
    Publishing date 2024-02-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.0000000000000436
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Antibody levels following booster SARS-CoV-2 vaccination among dialysis patients initially vaccinated with adenovirus vector-based vaccine.

    Willetts, Joanna / Ficociello, Linda H / Johnson, Curtis D / Alexander, Sandra E / Mullon, Claudy / Hymes, Jeffrey L

    Journal of nephrology

    2023  Volume 36, Issue 3, Page(s) 609–611

    MeSH term(s) Humans ; Adenovirus Vaccines ; Adenoviridae ; COVID-19 Vaccines ; SARS-CoV-2 ; Renal Dialysis ; COVID-19 ; Vaccines ; Vaccination
    Chemical Substances Adenovirus Vaccines ; COVID-19 Vaccines ; Vaccines
    Language English
    Publishing date 2023-01-23
    Publishing country Italy
    Document type Letter
    ZDB-ID 1093991-x
    ISSN 1724-6059 ; 1120-3625 ; 1121-8428
    ISSN (online) 1724-6059
    ISSN 1120-3625 ; 1121-8428
    DOI 10.1007/s40620-022-01559-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis.

    Medaura, Juan A / Zhou, Meijiao / Ficociello, Linda H / Anger, Michael S / Sprague, Stuart M

    American journal of nephrology

    2023  Volume 55, Issue 2, Page(s) 127–135

    Abstract: Introduction: Sucroferric oxyhydroxide (SO), a non-calcium, chewable, iron-based phosphate binder (PB), effectively lowers serum phosphorus (sP) concentrations while reducing pill burden relative to other PBs. To date, SO studies have largely examined ... ...

    Abstract Introduction: Sucroferric oxyhydroxide (SO), a non-calcium, chewable, iron-based phosphate binder (PB), effectively lowers serum phosphorus (sP) concentrations while reducing pill burden relative to other PBs. To date, SO studies have largely examined treatment-experienced, prevalent hemodialysis populations. We aimed to explore the role of first-line SO initiated during the first year of dialysis.
    Methods: We retrospectively analyzed deidentified data from adults receiving in-center hemodialysis who were prescribed SO monotherapy within the first year of hemodialysis as part of routine clinical care. All patients continuing SO monotherapy for 12 months were included. Changes from baseline in sP, achievement of sP ≤5.5 and ≤4.5 mg/dL, and other laboratory parameters were analyzed quarterly for 1 year.
    Results: The overall cohort included 596 patients, 286 of whom had a dialysis vintage ≤3 months. In the 3 months preceding SO initiation, sP rapidly increased (mean increases of 1.02 and 1.65 mg/dL in the overall cohort and incident cohort, respectively). SO treatment was associated with significant decreases in quarterly sP (mean decreases of 0.26-0.36; p < 0.0001 for each quarter and overall). While receiving SO, 55-60% of patients achieved sP ≤5.5 mg/dL and 21-24% achieved sP ≤4.5 mg/dL (p < 0.0001 for each quarter and overall vs. baseline). Daily PB pill burden was approximately 4 pills. Serum calcium concentrations increased and intact parathyroid hormone concentrations decreased during SO treatment (p < 0.0001 vs. baseline).
    Conclusions: Among patients on hemodialysis, initiating SO as a first-line PB resulted in significant reductions in sP while maintaining a relatively low PB pill burden.
    MeSH term(s) Adult ; Humans ; Phosphorus ; Hyperphosphatemia/drug therapy ; Hyperphosphatemia/etiology ; Retrospective Studies ; Renal Dialysis/adverse effects ; Renal Dialysis/methods ; Ferric Compounds/therapeutic use ; Sucrose ; Phosphates ; Drug Combinations
    Chemical Substances Phosphorus (27YLU75U4W) ; sucroferric oxyhydroxide ; Ferric Compounds ; Sucrose (57-50-1) ; ferric phosphate (N6BAA189V1) ; Phosphates ; Drug Combinations
    Language English
    Publishing date 2023-12-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 604540-6
    ISSN 1421-9670 ; 0250-8095
    ISSN (online) 1421-9670
    ISSN 0250-8095
    DOI 10.1159/000535754
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Global real-world data on hemodiafiltration: An opportunity to complement clinical trial evidence.

    Ficociello, Linda H / Busink, Ellen / Sawin, Dixie-Ann / Winter, Anke

    Seminars in dialysis

    2022  Volume 35, Issue 5, Page(s) 440–445

    Abstract: Hemodiafiltration (HDF) is a renal replacement therapy that utilizes both diffusive clearance and convective transport to achieve greater clearance of middle-molecular-weight solutes. Among other factors, important prerequisites for the implementation of ...

    Abstract Hemodiafiltration (HDF) is a renal replacement therapy that utilizes both diffusive clearance and convective transport to achieve greater clearance of middle-molecular-weight solutes. Among other factors, important prerequisites for the implementation of HDF include access to high-flux dialyzers, achievement of high blood flow rates, and availability of high volumes of sterile substitution/replacement fluids. Online hemodiafiltration (OL-HDF) is an established kidney replacement therapy, frequently used in many countries. Although in the United States, some prerequisites (e.g., access to high-flux dialyzers and achievement of high blood flow rates) for OL-HDF treatment are readily available; however, a machine capable of generating the online solution for OL-HDF is currently not available. As the clinical experience with HDF accumulates globally, it is worth examining the evidence for this kidney replacement therapy as used in routine clinical care. Such real-world evidence is increasingly recognized as valuable by clinicians and may inform regulatory decisions. In this review, we will focus on emerging global real-world data derived from routine clinical practices and examine how these data may complement those derived from clinical trials.
    MeSH term(s) Hemodiafiltration ; Humans ; Kidney Failure, Chronic/therapy ; Renal Dialysis
    Language English
    Publishing date 2022-04-19
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 1028193-9
    ISSN 1525-139X ; 0894-0959
    ISSN (online) 1525-139X
    ISSN 0894-0959
    DOI 10.1111/sdi.13085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization.

    Ficociello, Linda H / Willetts, Joanna / Mullon, Claudy / Johnson, Curtis / Anger, Michael S / Hymes, Jeffrey L

    International journal of nephrology and renovascular disease

    2022  Volume 15, Page(s) 319–321

    Language English
    Publishing date 2022-11-16
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2508160-3
    ISSN 1178-7058
    ISSN 1178-7058
    DOI 10.2147/IJNRD.S383215
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Switching from high-flux dialysis to hemodiafiltration: Cost-consequences for patients, providers, and payers.

    Hornig, Carsten / Apel, Christian / Ficociello, Linda H / Kendzia, Dana / Anger, Michael / Bowry, Sudhir K

    Seminars in dialysis

    2022  Volume 35, Issue 5, Page(s) 405–412

    Abstract: Hemodiafiltration (HDF) achieves a more efficient reduction of the uremic toxic load compared to standard high-flux hemodialysis (HF-HD) by virtue of the combined diffusive and convective clearances of a broad spectrum of uremic retention solutes. ... ...

    Abstract Hemodiafiltration (HDF) achieves a more efficient reduction of the uremic toxic load compared to standard high-flux hemodialysis (HF-HD) by virtue of the combined diffusive and convective clearances of a broad spectrum of uremic retention solutes. Clinical trials and registry data suggest that HDF improves patient outcomes. Despite the acknowledged need to improve survival rates of dialysis patients and the survival benefit HDF offers, there is little to no utilization in some countries (such as the US) in prescribing HDF to their patients. In this analysis, we present the healthcare value-based case for HDF (relative to HF-HD) from the patient, provider, and payor perspectives. The improved survival and reduced morbidity observed in studies conducted outside the US, as well as the reduced hospitalization, are attractive for each stakeholder. We also consider the potential barriers to greater utilization of HDF therapies, including unfounded concerns regarding additional costs of HDF, e.g., for the preparation and microbial testing of quality of substitution fluids. Ultrapure fluids are easily attainable and prepared from dialysis fluids using established "online" (OL) technologies. OL-HDF has matured to a level whereby little additional effort is required to safely implement it as all modern machine systems are today equipped with the OL-HDF functionality. Countries already convinced of the advantages of HF-HD are thus well positioned to make the transition to OL-HDF to achieve further clinical and associated economic benefits. Healthcare systems struggling to cope with the increasing demand for HD therapies would therefore, like patients, be beneficiaries in the long term with increased usage of OL-HDF for end stage kidney disease patients.
    MeSH term(s) Dialysis Solutions ; Hemodiafiltration ; Hospitalization ; Humans ; Kidney Failure, Chronic/therapy ; Renal Dialysis
    Chemical Substances Dialysis Solutions
    Language English
    Publishing date 2022-03-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1028193-9
    ISSN 1525-139X ; 0894-0959
    ISSN (online) 1525-139X
    ISSN 0894-0959
    DOI 10.1111/sdi.13075
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care.

    Rhee, Connie M / Zhou, Meijiao / Woznick, Rachael / Mullon, Claudy / Anger, Michael S / Ficociello, Linda H

    International urology and nephrology

    2022  Volume 55, Issue 2, Page(s) 377–387

    Abstract: Objective: Despite the growing number of elderly hemodialysis patients, the influence of age on nutritional parameters, serum phosphorus (sP), and use of phosphate-binder (PB) medications has not been well characterized. We aimed to describe age-related ...

    Abstract Objective: Despite the growing number of elderly hemodialysis patients, the influence of age on nutritional parameters, serum phosphorus (sP), and use of phosphate-binder (PB) medications has not been well characterized. We aimed to describe age-related differences in patient characteristics in a large, real-world cohort of maintenance hemodialysis patients, and to examine the impact of age on sP management with sucroferric oxyhydroxide (SO).
    Methods: We retrospectively analyzed de-identified data from 2017 adult, in-center hemodialysis patients who switched from another PB to SO monotherapy as part of routine clinical care. Changes in baseline PB pill burden, sP levels, and nutritional and dialytic clearance parameters were assessed across varying age groups through 6 months.
    Results: At baseline, older patients had lower mean sP, serum albumin, and pre-dialysis weights compared with younger patients. Prescription of SO was associated with a 62% increase in the proportion of patients achieving sP ≤ 5.5 mg/dl and a 42% reduction in daily pill burden. The proportion of patients achieving sP ≤ 5.5 mg/dl after transitioning to SO increased by 113, 96, 68, 77, 61, 37 and 40% among those aged 19-29, 30-39, 40-49, 50-59, 60-69, 70-79, and ≥ 80 years, respectively.
    Conclusions: Older patients had worse nutritional parameters, lower pill burden, and lower sP at baseline versus younger counterparts. Prescription of SO was associated with improved sP control and reduced pill burden across all ages.
    MeSH term(s) Adult ; Aged ; Humans ; Phosphorus ; Hyperphosphatemia/drug therapy ; Hyperphosphatemia/etiology ; Retrospective Studies ; Renal Dialysis ; Drug Combinations
    Chemical Substances Phosphorus (27YLU75U4W) ; sucroferric oxyhydroxide ; Drug Combinations
    Language English
    Publishing date 2022-08-11
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 204048-7
    ISSN 1573-2584 ; 0301-1623 ; 0042-1162
    ISSN (online) 1573-2584
    ISSN 0301-1623 ; 0042-1162
    DOI 10.1007/s11255-022-03327-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: An Innovative Approach to Minimizing Downtime in Continuous Kidney Replacement Therapy.

    Treu, Denny / Ashenuga, Michael / Massingham, Kara / Brugger, James / Medina, Luis / Ficociello, Linda H / Thompson, David

    ASAIO journal (American Society for Artificial Internal Organs : 1992)

    2023  Volume 69, Issue 6, Page(s) e250–e255

    Abstract: Continuous kidney replacement therapy (CKRT) is often utilized to stabilize patients with severe acute kidney injury associated with significant electrolyte abnormalities and/or oliguria and concomitant fluid accumulation. Circuit downtime may reduce ... ...

    Abstract Continuous kidney replacement therapy (CKRT) is often utilized to stabilize patients with severe acute kidney injury associated with significant electrolyte abnormalities and/or oliguria and concomitant fluid accumulation. Circuit downtime may reduce daily treatment time and affect delivered doses of CKRT. Studies have found clotting to be the leading cause of downtime and underdosing, which are associated with negative treatment outcomes. The NxStage Cartridge Express with Speedswap (NxStage Medical, Inc.) was designed to minimize downtime by allowing filter priming to occur in parallel with ongoing CKRT and by permitting filter exchanges without the need to replace the entire cartridge. Data from pilot studies suggest that filter exchanges using this system interrupt treatment by an average of 4 minutes per exchange-a considerable reduction from traditional systems that require treatment to be discontinued while the filter is primed, which can take 30 minutes or more. In addition to increasing patient time on therapy, this system has the potential to reduce costs for patients who require a high number of filter changes, and reduce nursing labor and environmental impact (reduced plastic waste). Future studies should confirm whether patients at higher risk of clotted/clogged filters benefit from CKRT with a system designed for rapid filter changes.
    MeSH term(s) Humans ; Acute Kidney Injury/prevention & control ; Blood Coagulation ; Continuous Renal Replacement Therapy ; Renal Replacement Therapy
    Language English
    Publishing date 2023-03-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 759982-1
    ISSN 1538-943X ; 0162-1432 ; 1058-2916
    ISSN (online) 1538-943X
    ISSN 0162-1432 ; 1058-2916
    DOI 10.1097/MAT.0000000000001928
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Effect of Citrate-Acidified Dialysate on Intact Parathyroid Hormone in Prevalent Hemodialysis Patients: A Matched Retrospective Cohort Study.

    Ficociello, Linda H / Zhou, Meijiao / Mullon, Claudy / Anger, Michael S / Kossmann, Robert J

    International journal of nephrology and renovascular disease

    2021  Volume 14, Page(s) 475–486

    Abstract: Background: It has been proposed that substituting citrate-acidified dialysate (CAD) solutions for acetate-acidified dialysate (AAD) could improve hemodynamics and dialysis tolerance and reduce the requirement for systemic anticoagulation. Citrate ... ...

    Abstract Background: It has been proposed that substituting citrate-acidified dialysate (CAD) solutions for acetate-acidified dialysate (AAD) could improve hemodynamics and dialysis tolerance and reduce the requirement for systemic anticoagulation. Citrate chelates ionized calcium, but long-term effects of CAD use during maintenance hemodialysis have not been well studied. While many studies of the effects of CAD on serum calcium and intact parathyroid hormone (iPTH) have been short-term or have been limited by sample size, we aimed to determine if there are any long-term (i.e., 6-month) changes from pre-dialysis iPTH levels when patients are switched from AAD to CAD.
    Methods: This retrospective cohort study compared various clinical parameters, including pre-dialysis iPTH and serum calcium as well as single pool Kt/V, from eligible patients who received in-center hemodialysis thrice-weekly in geographically matched CAD (n=3) or AAD clinics (n=12). CAD clinics were defined as clinics converting from AAD to CAD if >85% of the patients were prescribed CAD after implementation of CAD within the clinic.
    Results: Pre-dialysis iPTH was not significantly different from baseline to 6-month follow-up within either CAD or AAD clinics. Moreover, the mean change from baseline to month 6 in iPTH between patients (n=142) in CAD clinics (-17 pg/mL) and patients (n=671) in AAD clinics (13 pg/mL) was similar (
    Conclusion: Similar trends in single pool Kt/V, iPTH, and serum calcium levels were observed in clinics that switched from AAD to CAD versus the geographically matched AAD clinics. These results support CAD as a potential alternative to AAD in hemodialysis.
    Language English
    Publishing date 2021-12-24
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2508160-3
    ISSN 1178-7058
    ISSN 1178-7058
    DOI 10.2147/IJNRD.S340028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Real-World Performance of High-Flux Dialyzers in Patients With Hypoalbuminemia.

    Zhou, Meijiao / Ficociello, Linda H / Mullon, Claudy / Mooney, Ann / Williamson, Don / Anger, Michael S

    ASAIO journal (American Society for Artificial Internal Organs : 1992)

    2021  Volume 68, Issue 1, Page(s) 96–102

    Abstract: There is little research on factors that influence the choice of dialyzer in patients undergoing hemodialysis. In patients at risk for poorer outcomes, including those with hypoalbuminemia, understanding how this choice impacts clinical parameters could ... ...

    Abstract There is little research on factors that influence the choice of dialyzer in patients undergoing hemodialysis. In patients at risk for poorer outcomes, including those with hypoalbuminemia, understanding how this choice impacts clinical parameters could inform patient management. The objective of this real-world analysis was to evaluate the use and performance of four single-use (i.e., nonreuse [NR]), high-flux Optiflux dialyzers with varying surface areas (F160NR [1.5 m2], F180NR [1.7 m2], F200NR [1.9 m2], and F250NR [2.5 m2]) in patients (N = 271) with baseline hypoalbuminemia (≤3.5 g/dl) receiving hemodialysis at a medium-sized dialysis organization. Thrice weekly, in-center dialysis was delivered for 6 months without adjustments to the hemodialysis prescription. Larger dialyzers were more frequently used in men, patients with higher body mass indices, and those with diabetes. Increases in serum albumin from baseline (month 1) to month 6 (p < 0.05) were observed with all dialyzer sizes. A mean increase in hemoglobin of 0.31 g/dl was also observed (p < 0.001). Among patients exhibiting increased serum albumin levels (n = 177), reductions in the neutrophil-to-lymphocyte ratio, a marker of inflammation, were observed (mean: 0.90; p < 0.001). These results support the use of high-flux dialyzers in patients with hypoalbuminemia.
    MeSH term(s) Hemoglobins ; Humans ; Hypoalbuminemia/etiology ; Male ; Membranes, Artificial ; Renal Dialysis/adverse effects ; Serum Albumin
    Chemical Substances Hemoglobins ; Membranes, Artificial ; Serum Albumin
    Language English
    Publishing date 2021-06-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 759982-1
    ISSN 1538-943X ; 0162-1432 ; 1058-2916
    ISSN (online) 1538-943X
    ISSN 0162-1432 ; 1058-2916
    DOI 10.1097/MAT.0000000000001511
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top